



C-RAD has been selected by Australian Cancer Care Associates (CCA) for their cancer clinics across Australia

C-RAD announces today a new order for Catalyst+HD™ and Sentinel 4DCT™ from Australian Cancer Care Associates (CCA). The order includes multiple systems across the CCA network.

Cancer Care Associates (CCA) is an expanding Australian owned comprehensive cancer care provider. CCA is renowned for providing high quality patient care and the addition of C-RAD's state-of-the-art radiation therapy systems across the organisation will enhance accuracy and efficiency of patient treatment.

Damien Williams, Chief Operating Officer for the CCA Group, commented *"We are excited to be partnering with C-RAD long term and the opportunity to enhance our treatment platform with precise and marker free patient positioning via the C-RAD system"*.

Together with our Australian partners, Gamma Gurus Pty Ltd, we have built a strong relationship with Cancer Care Associates. Having utilised C-RAD's technology for many years this is a vital step to enhancing the standard of care with C-RAD's Surface Guided Radiation Therapy (SGRT) to all their sites.

"We are pleased to be able to deliver C-RAD's SGRT technology across the CCA network. We look forward supporting Cancer Care Associates for many years to come as this network expands into the future" says James Nguyen, Asia Pacific Sales Director.

The total order value is approximately 23 MSEK and includes multiple Catalyst+HD and Sentinel systems across the CCA network. Delivery and installation are expected to take place over the coming two years, starting second half of 2023.

"We are honoured for the partnership with CCA", said Cecilia de Leeuw, CEO and President of C-RAD AB. *This confirms C-RAD's SGRT technology to becoming the standard of care in radiation therapy and will ensure that patients across the CCA network receive the best treatments available".*

For further information:

Cecilia de Leeuw, CEO, +46 (0)18 751 33 22, investors@c-rad.com

Press Release
14 April 2023 12:40:00 CEST



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

[C-RAD has been selected by Australian Cancer Care Associates \(CCA\) for their cancer clinics across Australia](#)